Morrisville, NC, Dec 3, 2024 –
Jellatech, a biotechnology company revolutionizing health and longevity through sustainable, cell-cultured human collagen and complex proteins, is proud to announce the addition of two esteemed experts to its advisory board: Matthew Kane, an accomplished biotechnology leader, and Dr. Bill Polacheck, a renowned biomedical engineer and cell biologist.
Matthew Kane: Strategic Leadership in Biotechnology
Mr. Kane brings over two decades of biotechnology expertise to Jellatech’s advisory board. Currently serving as CEO of Celyad Oncology, he is a trailblazer in the development of advanced genetic medicines and cellular therapies. Previously, as CEO of Tune Therapeutics, he raised over $100M in financing and advanced groundbreaking epigenetic therapies into clinical studies.
As co-founder and former CEO of Precision BioSciences, Mr. Kane led initiatives that raised over $400M in funding, launched a successful IPO, and formed partnerships exceeding $4.7B in value. His proven ability to build and scale biotech companies will support Jellatech in commercial strategy, licensing, and advancing its therapeutic applications.
Dr. Bill Polacheck: Innovator in Biomechanics and Human Tissue Modeling
Dr. Polacheck is an Assistant Professor in the Joint Department of Biomedical Engineering at UNC and NC State and in Cell Biology and Physiology at the UNC School of Medicine. His pioneering research bridges molecular cell biology and mechanical engineering to recreate biomimetic tissue environments.
With a Ph.D. in Mechanical Engineering from M.I.T. and a wealth of experience at Boston University and Harvard University, Dr. Polacheck’s contributions have been recognized with prestigious awards, including the American Heart Association Career Development Award. His expertise in biomechanics, extracellular proteins, and 3D microfluidics will accelerate Jellatech’s advancements in human tissue modeling and collagen innovation.
Positioning Jellatech for Growth and Impact
“Matthew and Bill are exceptional leaders in their respective fields, and their combined expertise will be instrumental in driving Jellatech’s mission to transform human health and longevity,” said Stephanie Michelsen, CEO of Jellatech. “Matthew’s strategic vision in building biotech companies and Bill’s groundbreaking research in tissue modeling will guide us as we scale our platform and deliver revolutionary collagen-based solutions to the market.”
Jellatech is poised to leverage these partnerships as it advances its R&D, moves into GLP production, and scales up for commercialization.
